A previous study in liver diseases showed that CTCF combines with maternal hypomethylation imprinting control region (ICR) to promote the expression of lncRNA H19, which is a regulator of fatty liver, fibrosis, and other liver diseases (Li and Liu, 2020), suggesting that CTCF may play a role in NAFLD. Here, CTCF is linked to metabolic dysfunction-associated steatotic liver disease.